Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 3,579 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Peripheral Arterial Disease, Cardiovascular Disease, Peripheral Vascular Disease
Interventions: Paclitaxel administration using the OPC; Other
Lead sponsor: Horizons International Peripheral Group; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 17
States / cities: Fairhope, Alabama • Jacksonville, Florida • Pensacola, Florida + 13 more

Conditions: Sarcoma
Interventions: diagnostic imaging; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Spinal Cord Neoplasm
Interventions: Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography; Drug · Device · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cutaneous T-Cell Lymphoma
Interventions: tofacitinib 2% cream; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pain
Interventions: Matrix Transdermal Fentanyl/CHADD Drug Delivery System, Placebo Patch; Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 15
States / cities: Phoenix, Arizona • Jacksonville, Florida • Marietta, Georgia + 12 more

Conditions: Cervical Intraepithelial Neoplasia Grade 2/3, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2, High Grade Cervical Intraepithelial Neoplasia
Interventions: Imiquimod, Topical Fluorouracil; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acute Ischemic Stroke
Interventions: alfimeprase; Drug
Lead sponsor: ARCA Biopharma, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Los Angeles, California • Chicago, Illinois • Des Moines, Iowa + 13 more

Conditions: Vaginitis, Vulvar Diseases
Interventions: Vaginitis panel; Diagnostic Test
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Epidermolysis Bullosa
Interventions: topical BPM31510 3.0% Cream; Drug
Lead sponsor: Shasa Hu; Other
Eligibility: 12 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Eosinophilic Esophagitis, Milk Allergy
Interventions: Viaskin Milk 500 mcg, Viaskin Placebo; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 4 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Seborrheic Keratosis (SK)
Interventions: A-101 25%, A-101 32.5%, A-101 40%, A-101 Vehicle; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hypogonadism
Interventions: Nasobol®, Androderm® (Positive Control); Drug
Lead sponsor: Acerus Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Tucson, Arizona • Burbank, California • Miami Gardens, Florida + 3 more

Conditions: Bipolar Depression
Interventions: EmSam; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis
Interventions: Buprenorphine transdermal patch, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 44
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Psoriasis
Interventions: Shave Biopsy of Psoriasis Lesion; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Amblyopia
Interventions: CureSight, Patching; Device
Lead sponsor: NovaSight; Industry
Eligibility: 4 Years to 8 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Virginia Beach, Virginia

Conditions: Actinic Keratosis (AK)
Interventions: Investigational drug, Photodynamic therapy; Drug · Device
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Compare Bioequivalence Patches Previously Used in the NP101-007 Study
Interventions: NP101, sumatriptan succinate; Drug
Lead sponsor: NuPathe Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Cystic Fibrosis, Contraception
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 562 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 7 more

Conditions: Pre-Gestational Diabetes, Type2diabetes, Pregnancy in Diabetic, Pregnancy, High Risk
Interventions: DEXCOM G7 PRO Continuous Glucose Monitor, Patient mHealth app linked to a provider dashboard, Care team coaching for medical and social needs (HUB), Provider dashboard; Device · Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pain Management After Breast Biopsy
Interventions: Lidocaine Ropivacaine, Lidocaine alone; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Head Lice
Interventions: Spinosad (the active ingredient in NatrOVA), placebo; Drug
Lead sponsor: ParaPRO LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: PAD - Peripheral Arterial Disease, PAD, Dissection, Arterial Dissection, Peripheral Arterial Disease, Peripheral Vascular Diseases
Interventions: The Tack Endovascular System; Device
Lead sponsor: Spectranetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Thornton, Colorado • Hartford, Connecticut • Fort Lauderdale, Florida + 7 more

Conditions: Vitiligo, Depigmented Scars, Depigmentation
Interventions: MKTP (melanocyte keratinocyte transplant procedure), Collagen Dressing, Vaseline Impregnated Gauze, Carbon Dioxide Laser, Dermabrasion; Procedure · Device
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Search by objective public record fields.

The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee

Infrared Thermography in Finding Skin Lesions in Patients With Kaposi's Sarcoma

FDG PET-MRI for the Diagnosis of Spinal Cord Lesions

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain

Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia

Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke

Prospective Evaluation of Infectious Vulvovaginitis on Wound Complication Rates After Vulvar Excision for Premalignant Lesions

Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa

Milk Patch for Eosinophilic Esophagitis

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

Efficacy and Tolerability of an Intra-Nasal Testosterone Product

A Pilot Study Assessing EmSam in Bipolar Depression

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

Role of Chemokine and Chemokine Receptor in Psoriasis

CURESIGHT BINOCULAR AMBLYOPIA TREATMENT STUDY

An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face

Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults

Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis

Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching

Comparison of Long vs. Short Acting Anesthesia for Improving Pain Management After Breast Biopsy

Phototoxicity Potential of NatrOVA Creme Rinse - 1%

Tack Optimized Balloon Angioplasty Post-Market Study

Comparative Study Using Dermabrasion vs CO2 Laser & Collagen Dressing vs Vaseline Gauze in MKTP